James E. Wooldridge

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial”.

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Cancer Cell(2024)10.1016/j.ccell.2024.10.007

N/A

1.3DataRank · unranked

59 citations

Robert M. Morrison, Amiran Dzutsev, Arivarasan Karunamurthy, Joë-Marc Chauvin, F. Amatore +48 more

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0605

N/A

0.272DataRank · unranked

4 citations

Joë-Marc Chauvin, Robert Morrison, Yulong Bai, Jie Sun, Hong Wang +22 more

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Research Square(2022)10.21203/rs.3.rs-2235839/v1

N/A

0DataRank · unranked

1 citations

Arivarasan Karunamurthy, Joë-Marc Chauvin, Robert M. Morrison, Yulong Bai, Jie Sun +40 more